Related Experiment Video

Updated: Mar 7, 2026

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.8K

LncRNA H19 promotes atherosclerosis by regulating MAPK and NF-kB signaling pathway

J-X Pan1

  • 1Department of Cardiology, University-Town Hospital of Chongqing Medical University, Chongqing, China. 274047837@qq.com.

European Review for Medical and Pharmacological Sciences
|February 7, 2017
PubMed

Insights

Long non-coding RNA H19 is highly expressed in atherosclerosis patients. Overexpressing H19 in HUVEC cells increased proliferation and suppressed apoptosis, suggesting H19 as a potential therapeutic target for atherosclerosis.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Genomics

Background:

  • Atherosclerosis is a leading global cause of mortality, driven by complex mechanisms and risk factors.
  • The precise role of long non-coding RNAs (lncRNAs) in atherosclerosis pathogenesis remains largely undefined.
  • lncRNAs are implicated in various biological and pathological processes.

Purpose of the Study:

  • To investigate the expression of lncRNA H19 in atherosclerosis patients.
  • To determine the functional role of lncRNA H19 in endothelial cell proliferation and apoptosis.
  • To explore the association between lncRNA H19 and key signaling pathways (p38, p65) in atherosclerosis.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) to measure lncRNA H19 expression in 42 atherosclerosis patients and 37 healthy controls.
  • Overexpression of lncRNA H19 in Human Umbilical Vein Endothelial Cells (HUVEC).
  • Assessment of HUVEC proliferation and apoptosis, and Western blot analysis for p38 and p65 protein levels.

Main Results:

  • lncRNA H19 expression was significantly higher in atherosclerosis patients compared to healthy individuals.
  • Overexpression of lncRNA H19 in HUVEC cells enhanced cell proliferation and inhibited apoptosis.
  • Increased expression of p38 and p65 proteins was observed following lncRNA H19 overexpression.

Conclusions:

  • lncRNA H19 is upregulated in atherosclerosis and may play a critical role in disease progression.
  • lncRNA H19 promotes endothelial cell proliferation and survival, potentially via the p38/p65 pathways.
  • lncRNA H19 represents a promising molecular target for the development of novel atherosclerosis therapies.
Abstract

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.8K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.2K
Types of RNA01:20

Types of RNA

Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
10.2K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
540
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.7K